Schools will require parental consent before vaccinating students, and a public awareness drive will also be launched, ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

GSK is to provide a supply of Cervarix® (Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed)) to four new GAVI demonstration projects at a significantly discounted ...

A new study has found that less than a quarter as many women under the age of 25 died of cervical cancer in the United States from 2019 to 2021 as died in an equivalent period from 1992 to 1994.

Similarly, the vaccine market has seen launches like Mercks’ Gardasil and GSK’s Cervarix which are under patent. Pfizer also recently launched Prevnar-13 under Wyeth which has the potential to ...

Gardasil dominates the market for HPV vaccines but still faces competition from GSK plc (NYSE: GSK) bivalent HPV vaccine Cervarix. 2) Merck's Pipeline of Drugs Is Worth More Than $50 Billion In ...

The Business Research Company The Business Research Company’s Cervarix Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts t ...